Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – XELJANZ

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Tofacitinib Testmiljö

Tofacitinib

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford). 2010;49(8):1563-9.

  2. Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d'Elia H, Neovius M et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther. 2015;17(1):118.

  3. Löfvendahl S, Theander E, Svensson Å, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. PLoS One. 2014;9(5):e98024.

  4. Büsch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39(1):57-68.

  5. Berthold E, Månsson B, Kahn R. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther. 2019;21(1):218.

  6. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - XELJANZ (tofacitinib). Drugs@FDA [www]. [updated 2012-12-28, cited 2024-04-25].

  7. Xeljanz (tofacitinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2023-12-07, cited 2024-04-22]

  8. Xie R, Deng C, Wang Q, Kanik KS, Nicholas T, Menon S. Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
. Int J Clin Pharmacol Ther. 2019 Jul 19;

  9. Ma G, Xie R, Strober B, Langley R, Ito K, Krishnaswami S et al. Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis. Clin Pharmacol Drug Dev. 2018;7(6):587-596.

  10. Vong C, Martin SW, Deng C, Xie R, Ito K, Su C et al. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev. 2021;10(3):229-240.

  11. Eder L, Gladman DD, Mease P, Pollock RA, Luna R, Aydin SZ et al. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023;9(1):.

  12. Martinez-Molina C, Feliu A, Park HS, Juanes A, Diaz-Torne C, Vidal S et al. Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?. J Clin Med. 2024;13(8):.

  13. Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG et al. Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials. J Drugs Dermatol. 2016;15(5):568-80.

  14. Huang J, Deng S, Li J, Tang Y, Liu F, Liu Y et al. Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study. Acta Derm Venereol. 2023;103:adv13475.

  15. Charles-Schoeman C, DeMasi R, Valdez H, Soma K, Hwang LJ, Boy MG et al. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019;71(9):1450-1459.

  16. Kuwana M, Sugiyama N, Momohara S, Atsumi T, Takei S, Tamura N et al. Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance. Mod Rheumatol. 2024;34(2):272-286.

  17. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P et al. Long-term safety of tofacitinib up to 95 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6(3):e001395.

  18. Balanescu AR, Citera G, Pascual-Ramos V, Bhatt DL, Connell CA, Gold D et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2022;81(11):1491-1503.

  19. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843-7.

  20. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford). 2010;49(8):1563-9.
  2. Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d'Elia H, Neovius M et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther. 2015;17(1):118.
  3. Löfvendahl S, Theander E, Svensson Å, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. PLoS One. 2014;9(5):e98024.
  4. Büsch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39(1):57-68.
  5. Berthold E, Månsson B, Kahn R. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther. 2019;21(1):218.
  6. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - XELJANZ (tofacitinib). Drugs@FDA [www]. [updated 2012-12-28, cited 2024-04-25].
  7. Xeljanz (tofacitinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2023-12-07, cited 2024-04-22]
  8. Xie R, Deng C, Wang Q, Kanik KS, Nicholas T, Menon S. Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
. Int J Clin Pharmacol Ther. 2019 Jul 19;
  9. Ma G, Xie R, Strober B, Langley R, Ito K, Krishnaswami S et al. Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis. Clin Pharmacol Drug Dev. 2018;7(6):587-596.
  10. Vong C, Martin SW, Deng C, Xie R, Ito K, Su C et al. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev. 2021;10(3):229-240.
  11. Eder L, Gladman DD, Mease P, Pollock RA, Luna R, Aydin SZ et al. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023;9(1):.
  12. Martinez-Molina C, Feliu A, Park HS, Juanes A, Diaz-Torne C, Vidal S et al. Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?. J Clin Med. 2024;13(8):.
  13. Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG et al. Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials. J Drugs Dermatol. 2016;15(5):568-80.
  14. Huang J, Deng S, Li J, Tang Y, Liu F, Liu Y et al. Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study. Acta Derm Venereol. 2023;103:adv13475.
  15. Charles-Schoeman C, DeMasi R, Valdez H, Soma K, Hwang LJ, Boy MG et al. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019;71(9):1450-1459.
  16. Kuwana M, Sugiyama N, Momohara S, Atsumi T, Takei S, Tamura N et al. Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance. Mod Rheumatol. 2024;34(2):272-286.
  17. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P et al. Long-term safety of tofacitinib up to 95 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6(3):e001395.
  18. Balanescu AR, Citera G, Pascual-Ramos V, Bhatt DL, Connell CA, Gold D et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2022;81(11):1491-1503.
  19. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843-7.
  20. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]